Related Experiment Video
Updated: Jun 21, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Systemic therapy for recurrent endometrial cancer: a review of North American trials
Thanh H Dellinger1, Bradley J Monk
1Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Building 56, Suite 260, 101 The City Drive South, Orange County, CA 92868-3298, USA. tdelling@uci.edu
Abstract:
While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
